Author contributions: Jamal Ahmad: Conceptualization
Who Should Consider GLP-1 Therapy FDA indications for weight loss require: BMI 30 (obesity), or BMI 27 (overweight) with at least one weight-related condition hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or similar These thresholds set eligibility, but they don't answer the more important question: who benefits most
doi: 10.3389/fneph.2024.1390783 Received 23 February 2024 Accepted 15 May 2024 Published 04 June 2024 Volume 4 - 2024 Edited by Duvuru Geetha, Johns Hopkins Medicine, United States Reviewed by Dhanunjay Mukhi, University of Pennsylvania, United States Enrique Morales, CSUR complex glomerular pathology, Spain Updates Copyright 2024 Gholizadeh Ghozloujeh, Singh, Jhaveri, Shah, Lerma, Abdipour and Norouzi
Contrave for weight loss price varies by pharmacy and whether a manufacturer savings card is applied Currax Pharmaceuticals (Contraves maker) has historically offered discount programs
The lab-made version, Tozuleristide, creates a kind of light-up 'paint' under near-infrared that has allowed researchers to see cancerous clusters as small as a few hundred cells in rodent studies
Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D
